Opdivo along with Yervoy displays treatment for dMMR or MSI-H patients with mCRC

Bristol-Myers Squibb Company asserted new data from a cohort of the Phase 2 CheckMate-142 trial assessing Opdivo and Yervoy for the treatment of patients with DNA mismatch repair deficient microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). With a median of 13.4 months of follow-up, the primary endpoint of objective response rate (ORR) per investigator assessment was 55% (95% CI: 45.2 to 63.8). Responses were durable, with median duration of response not yet reached and 94% of responses ongoing at time of data cutoff. The overall survival (OS) rate at one year was 85% (95% CI: 77.0 to 90.2), and median OS was not yet reached. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 32% of patients receiving the Opdivo plus Yervoy combination.

Thierry André, M.D., Head of the Medical Oncology Department in St. Antoine Hospital said “The combination of Opdivo and Yervoy may represent an important advance for these distinct biomarker-defined patients, who historically have poorer outcomes compared to metastatic colorectal cancer patients whose tumors are mismatch repair proficient or microsatellite stable.”